Adocia announced positive results from a clinical pharmacology study comparing BioChaperone (BC) Lispro formulations employing insulin lispro from two different sources, a biosimilar from Tonghua Dongbao (THDB) and the brand, Humalog®, from Eli Lilly. This randomized, cross-over, double-blind, euglycemic clamp study was conducted on 30 people with type 1 diabetes. The study aimed to assess and compare the pharmacodynamic and pharmacokinetic properties as well as the safety of the four following formulations: BC Lispro (Adocia) composed of BioChaperone® and Tonghua Dongbao ’s insulin lispro. BC Lispro (Adocia) composed of BioChaperone® and the insulin lispro, Humalog® .Humalog® (Eli Lilly) approved in the USA. Humalog® (Eli Lilly) approved in Europe.